Low
₹1,330.60
High
₹1,387.70
| Previous Close | ₹1,359.20 |
|---|---|
| Day's Range | ₹1,330.60 - ₹1,387.70 |
| Open | ₹1,387.70 |
| 52 Week Range | ₹1,085.00 - ₹1,740.00 |
| Volume | 7,674 |
| Market Cap | ₹0.00 |
| Previous Close | ₹1,359.45 |
|---|---|
| Day's Range | ₹1,329.60 - ₹1,382.05 |
| Open | ₹1,382.05 |
| 52 Week Range | ₹1,083.50 - ₹1,750.00 |
| Volume | 901 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 103.71 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.37 |
| Price/Earning (TTM) | 21.01 |
| TTM EPS (₹) | 64.70 |
| P/E Ratio | 16.10 |
| Book Value(₹) | 3.50 |
| PAT Margin (%) | 42.23 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 25.90 |
| Trade Value ( ₹ in Lacs) | 12.17 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.37 |
| Price/Earning (TTM) | 21.01 |
| TTM EPS (₹) | 64.70 |
| P/E Ratio | 16.10 |
| Book Value(₹) | 3.50 |
| PAT Margin (%) | 42.23 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 25.90 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 222.35 | 905.3 |
| Expenses | N/A | N/A |
| PBT | 158.63 | 639.28 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 126.44 | 475.6 |
| Founded | 1972 |
|---|---|
| Managing Director | Dhirendra Dubey |
| NSE Symbol | 3BBLACKBIO |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,22,990.76 | 1,762.95 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,56,309.91 | 9,655.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,73,603.69 | 4,564.10 | 3,532.60 - 3,532.60 |
| Laurus Labs Ltd. | 1,21,300.09 | 2,245.00 | 917.95 - 917.95 |
| Lenskart Solutions Ltd. | 1,18,620.68 | 678.80 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,18,303.95 | 1,186.00 | 835.50 - 835.50 |
| Apollo Hospitals Enterprise Ltd. | 1,17,874.66 | 8,198.00 | 6,696.50 - 6,696.50 |
| Dr. Reddy's Laboratories Ltd. | 1,11,721.96 | 1,338.50 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,09,628.04 | 1,357.00 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,01,658.66 | 2,461.20 | 1,909.70 - 1,909.70 |
No Records Found
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR’), 3B BlackBio Dx has informed that the 54th Annual General Meeting of the Company is scheduled to be held on Tuesday,29th September, 2026 at 11:30 AM (IST) through Video Conferencing (‘VC’)/Other Audio-Visual Means (‘OAVM’). In accordance with the provisions of Regulation 42 of the SEBI LODR, the Register of Members and Share Transfer Books of the Company will remain closed from Wednesday, 23rd September 2026 to Tuesday, 29th September 2026 for the purpose of Annual General Meeting and Dividend for the Financial Year ended 31st March, 2026. Pursuant to the provisions of SEBI LODR, the company has informed that the Dividend for the Financial Year 2025-26 shall be paid on or after Monday, 5th October 2026 to those members whose names appears in the Register of members as on the Record date of Tuesday, 22nd September 2026. Further, pursuant to the provisions of Regulation 44 of the SEBI LODR, the Company is providing remote e-voting facility to the members to cast their vote(s) electronically. The cut-off date for the purpose of determining eligibility of members for remote e-voting is Tuesday, 22nd September 2026. The Remote e-Voting period will commence on Saturday, 26th September 2026 at 9.00 AM (IST) and ends on Monday, 28th September 2026 at 5.00 PM (IST).
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, Mercury Laboratories has informed that a meeting of the Board of Directors of the Company will be held on Thursday, November 05, 2026, to consider and approve the Unaudited Financial Results for the quarter and half year ended on September 30, 2026. Further, as per the Company’s Code of Conduct for Prevention of Insider Trading, the company has informed that, the ‘Trading Window’ has already been closed with effect from October 01, 2026 and shall continue to remain closed till 48 hours after the declaration of the unaudited financial results for the quarter and half year ended on September 30, 2026.
The above information is a part of company’s filings submitted to BSE.
With reference to its Letter dated 28th October 2026 vide which it has submitted the unaudited Financial Results (Standalone and Consolidated) of the Company for the Second Quarter and half year ended 30th September 2026, Sudeep Pharma has submitted copies of the Extract of unaudited Financial Results of the Company for the Second Quarter and half year ended 30th September 2026, on Consolidated basis, published in Business Standard, English language newspaper, Ahmedabad, Gujarat Samachar and Vadodara Samachar, Regional language newspapers at Vadodara, Gujarat on 29th October 2026. The above information is also available on the Company’s website at https://www.sudeeppharma.com/.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of 3B Blackbio Dx Ltd. is ₹1,359.20 as of 2026-10-29.
The market capitalisation of 3B Blackbio Dx Ltd. is ₹1,166.77 as of 2026-10-29.
The 1-year return of 3B Blackbio Dx Ltd. is % as of .
The P/E ratio of 3B Blackbio Dx Ltd. is 16.10 as of 2026-10-30.
The 52-week high and low of 3B Blackbio Dx Ltd. are ₹1,740.00 and ₹1,085.00, respectively, as of 2026-10-29.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.